Protalix BioTherapeutics

17/12/2025

https://ir.protalix.com/node/14646/pdf

17/12/2025

https://ir.protalix.com/news-releases/news-release-details/protalix-biotherapeutics-and-secarna-pharmaceuticals-enter

11/09/2024

HCW Global Investment Conference: Social Media Kit

03/01/2023

Protalix BioTherapeutics Issues 2023 Letter to Stockholders

Press Releases  View printer-friendly version Back Protalix BioTherapeutics Issues 2023 Letter to Stockholders Jan 3 PDF Version CARMIEL, , /PRNewswire/ -- (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant thera...

05/12/2022

Protalix and Chiesi Global Rare Diseases today announced that the U.S. FDA has accepted the resubmitted Biologics License Application (BLA) for pegunigalsidase alfa (PRX-102) for the proposed treatment of adult patients with Fabry disease. The FDA indicated in the BLA filing communication letter that the resubmitted BLA was considered a complete, class 2 response and set an action date of May 9, 2023, under the Prescription Drug User Fee Act (PDUFA). https://bit.ly/3VyBxCm

05/12/2022

Protalix's KOL event on Fabry disease and PRX-102 (pegunigalsidase alfa) will begin today, December 5, 2022 at 8:30 a.m. ET. Register for the event here: https://bit.ly/3VndKoI

01/12/2022

Join us on Monday, December 5, 2022 at 8:30 a.m. EST for a KOL event on Fabry disease and PRX-102 (pegunigalsidase alfa). A live Q&A session will follow the formal presentations. For event details: https://bit.ly/3VndKoI

28/11/2022

Save the date- Protalix will host a KOL event on Fabry disease and PRX-102 (pegunigalsidase alfa) on Monday, December 5th at 8:30 a.m. EST. Myrl D. Holida, PA (University of Iowa Stead Family Children’s Hospital) will discuss the PRX-102 robust clinical program for the potential treatment of patients suffering from Fabry disease and Protalix's leadership team will provide a regulatory update regarding PRX-102. To register for the event: https://bit.ly/3VndKoI

15/11/2022

Protalix CEO Dror Bashan commented on the recent BLA resubmission to the FDA for PRX-102 for the treatment of adult patients with Fabry disease. For Q3 2022 and recent business highlights: https://bit.ly/3O5oMwv

14/11/2022

Our CEO Dror Bashan commented on Protalix and Chiesi Global Rare Diseases' BLA resubmission and shared goal of achieving regulatory approval and making PRX-102 (pegunigalsidase alfa) available to patients with in the U.S.: https://bit.ly/3X1RIti

14/11/2022

Protalix today reported financial results for the third quarter ended September 30, 2022 and provided a business update on recent corporate and regulatory developments. Management will host a conference call and webcast today at 8:30 a.m. EST, for details:

Press Releases  View printer-friendly version Back Protalix BioTherapeutics Reports Third Quarter 2022 Financial and Business Results Nov 14 PDF Version Company to host conference call and webcast today at CARMIEL, , /PRNewswire/ -- (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focu...

14/11/2022

Protalix and Chiesi Global Rare Diseases today announced the resubmission on November 9, 2022 of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for PRX-102 (pegunigalsidase alfa) for the treatment of adult patients with Fabry disease. Pegunigalsidase alfa is a purposefully-designed, long-acting recombinant, PEGylated, cross-linked α-galactosidase-A investigational product candidate. Learn more: https://bit.ly/3X1RIti